Novartis heads to FDA with Rhapsido after phase 3 win in untapped chronic hives subtype
18th February 2026 Uncategorised 0Less than half a year after winning an inaugural green light in chronic hives, Novartis’ oral BTK inhibitor Rhapsido is jockeying to expand its urticaria reach into a new indication where it has the potential to become the first targeted therapy.
More: Novartis heads to FDA with Rhapsido after phase 3 win in untapped chronic hives subtype
Source: fierce